NEXIMMUNE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.37 USD | -1.17% |
|
-3.44% | +51.80% |
| 17/04 | North American Morning Briefing : Stock Futures -2- | DJ |
| 16/04 | NexImmune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 2.35M 196M |
|---|---|---|---|---|---|
| Net income 2022 | -62M -5.17B | Net income 2023 | -32M -2.67B | EV / Sales 2022 | - |
| Net cash position 2022 | 33.62M 2.8B | Net cash position 2023 | 3.13M 261M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.09
x | P/E ratio 2023 |
-0.07
x | Employees | 6 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 79.29% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -1.17% | ||
| 1 week | -3.44% | ||
| Current month | -39.93% | ||
| 1 month | -40.77% | ||
| 3 months | -37.01% | ||
| 6 months | -18.60% | ||
| Current year | +51.80% |
1 week
3.26
3.89
1 month
3.015.72
Current year
2.3228.69
1 year
1.2528.69
3 years
1.25511.75
5 years
1.25700.00
10 years
1.25700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kristi Jones
CEO | Chief Executive Officer | 60 | 01/17/01 |
Mathias Oelke
FOU | Founder | 56 | 07/11/07 |
Tonya Catterton
CMP | Compliance Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sol Barer
CHM | Chairman | 76 | 16/19/16 |
Zheng Bin Yao
BRD | Director/Board Member | 58 | 01/17/01 |
Alan S. Roemer
BRD | Director/Board Member | 54 | 01/17/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.37 | -1.17% | 3,391 |
| 25/24/25 | 3.41 | +4.60% | 7,330 |
| 24/24/24 | 3.26 | -4.96% | 12,753 |
| 23/24/23 | 3.43 | -5.90% | 6,785 |
| 22/24/22 | 3.645 | +4.44% | 45,019 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
NexImmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to immunotherapy designed to employ the bodyâs own T cells to generate an immune response that mimics natural biology. Its product candidates include NEXI-001 in acute myeloid leukemia (AML); NEXI-002 in multiple myeloma (MM), and NEXI-003, a solid tumor product candidate for Human papillomavirus (HPV) related cancers. The Company provides Artificial Immune Modulation (AIM), which is a nanoparticle technology platform. Its AIM technology enables it to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. The AIM nanoparticles employ signaling proteins to deliver instructions to T cells directing a desired immune response. The Company is also developing new AIM nanoparticle constructs and modalities for clinical evaluation in oncology and autoimmune disorders.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +51.80% | 4.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- NEXI Stock
